Structure Therapeutics (GPCR) Competitors $17.59 -0.21 (-1.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.60 +0.02 (+0.09%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. AKRO, ACLX, ACAD, VKTX, SRRK, PTCT, SWTX, MLTX, PTGX, and AAPGShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics Scholar Rock PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International Structure Therapeutics (NASDAQ:GPCR) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Does the media prefer GPCR or AKRO? In the previous week, Akero Therapeutics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Akero Therapeutics and 4 mentions for Structure Therapeutics. Akero Therapeutics' average media sentiment score of 1.29 beat Structure Therapeutics' score of 0.99 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, GPCR or AKRO? Structure Therapeutics has a beta of -1.87, meaning that its stock price is 287% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Do institutionals & insiders hold more shares of GPCR or AKRO? 91.8% of Structure Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, GPCR or AKRO? Akero Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-20.22Akero TherapeuticsN/AN/A-$252.06M-$1.95-24.81 Do analysts recommend GPCR or AKRO? Structure Therapeutics presently has a consensus target price of $76.17, indicating a potential upside of 333.01%. Akero Therapeutics has a consensus target price of $82.50, indicating a potential upside of 70.56%. Given Structure Therapeutics' higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GPCR or AKRO more profitable? Akero Therapeutics' return on equity of -15.19% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Akero Therapeutics N/A -15.19%-13.97% SummaryStructure Therapeutics beats Akero Therapeutics on 7 of the 12 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-20.2217.6228.6723.80Price / SalesN/A179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book1.168.508.275.55Net Income-$122.53M-$55.06M$3.24B$259.03M7 Day Performance-1.95%-3.98%-3.69%-4.59%1 Month Performance-13.94%9.59%4.33%4.46%1 Year Performance-50.98%6.72%25.95%18.03% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.0602 of 5 stars$17.59-1.2%$76.17+333.0%-51.7%$1.02BN/A-20.22136News CoverageUpcoming EarningsGap UpAKROAkero Therapeutics3.9641 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A-25.2530Positive NewsUpcoming EarningsACLXArcellx2.6029 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.93B$107.94M-23.6180News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.0001 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.89B$957.80M16.51510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.7757 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.87BN/A-21.7020Short Interest ↑SRRKScholar Rock3.8123 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.70B$33.19M-14.66140News CoverageUpcoming EarningsAnalyst ForecastPTCTPTC Therapeutics4.4836 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.55B$806.78M6.811,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsMLTXMoonLake Immunotherapeutics2.7013 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.53BN/A-23.682News CoverageUpcoming EarningsPTGXProtagonist Therapeutics2.1351 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.42B$434.43M75.01120Positive NewsUpcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600 Related Companies and Tools Related Companies Akero Therapeutics Alternatives Arcellx Alternatives ACADIA Pharmaceuticals Alternatives Viking Therapeutics Alternatives Scholar Rock Alternatives PTC Therapeutics Alternatives SpringWorks Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Protagonist Therapeutics Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts